Stephen C. Glover - Jun 15, 2021 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role
Director
Signature
/s/ Hillary Yegen, attorney-in-fact
Stock symbol
PDSB
Transactions as of
Jun 15, 2021
Transactions value $
$49,997
Form type
4
Date filed
6/17/2021, 07:15 PM
Next filing
Jun 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PDSB Common Stock Purchase $50K +5.88K +10.16% $8.50 63.8K Jun 15, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PDSB Stock Option (Right to Buy) Award $0 +9K $0.00 9K Jun 17, 2021 Common Stock 9K $9.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021.
F2 The Stock Option will vest in full and become fully exercisable on June 17, 2022.